Study of GenomeDx's Decipher® Prostate Cancer Test Selected as Best of ASTRO 2015
Proprietary genomic test used to predict cancer recurrence following prostate surgery and radiation, to be featured at American Society for Therapeutic Radiology and Oncology Annual Meeting
SAN DIEGO, Oct. 14, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that validation data for its Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer, will be presented next week at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Antonio, Texas. The abstract was also selected for the 2015 Best of ASTRO, a two-day meeting in November providing a review of the most relevant, highly-rated abstracts from the 2015 ASTRO Annual Meeting.
The abstract, titled "Validation of a Genomic Classifier for Prediction of Metastasis Following Postoperative Salvage Radiation Therapy," will be presented at 1:15 p.m. CDT on Wednesday, October 21. Robert Den, M.D., assistant professor of radiation oncology and cancer biology at Thomas Jefferson University, will deliver the presentation as part of the scientific session in room 217.
About Decipher® Prostate Cancer Classifier
Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by radiation oncologists and urologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. Decipher offers valuable insight that is distinct from clinical measures of risk including PSA and Gleason score. Studies of thousands of patients from leading cancer centers, published in more than 20 peer-reviewed journals, demonstrate that Decipher can accurately predict metastatic disease, identify patients most likely to benefit from therapeutic intervention, and lead to significant cost-savings for healthcare systems by reducing unnecessary procedures. Decipher is covered by Medicare and multiple private insurance plans in the US representing over 190 million covered lives.
Learn more at www.DecipherTest.com
About GenomeDx Biosciences
GenomeDx Biosciences is a genomic information company changing the landscape of urologic cancer patient care with innovative genomic solutions that empower physicians and patients to make more informed decisions about patient treatment. Using advanced cloud-based bioinformatics to mine vast amounts of genomic data, the company develops and commercializes proprietary clinical tests that provide actionable information to answer key clinical questions in patient management. GenomeDx's Decipher® is a genomic test that provides an assessment of tumor aggressiveness and is used by urologists and radiation oncologists to determine who to treat and how to treat them in order to offer the most effective and least harmful course of therapy. In partnership with leading medical centers, GenomeDx is building Decipher GRIDTM, the world's largest clinically-annotated genomic expression database in urologic cancer created to enable improvements to precision medicine in patient care. GenomeDx is based in San Diego and Vancouver, British Columbia.
Learn more at www.GenomeDx.com
Media Contact:
Ian Stone
Canale Communications
619-849-5388
[email protected]
SOURCE GenomeDx Biosciences
Share this article